This research focuses on early-disease identification of Cerebral Amyloid Angiopathy (CAA) in Australia, a condition causing unexpected brain bleeds, disability, and dementia. With an unknown prevalence, especially in those over 65, this project aims to identify CAA early.

There's a critical need to recognize CAA in Australia due to its severe impact on individuals, causing recurrent brain bleeds and leading to dementia. With an unknown prevalence, it might affect up to 8% of people over 65. Although there's currently no treatment, upcoming medications could potentially slow or reverse the disease. However, early identification is key. This project at Royal Brisbane and Women's Hospital (RBWH) aims to identify an early stage of CAA, creating a registry for patients.

This project seeks to establish a clinical registry for CAA patients in the RBWH catchment, providing the foundation for a broader Queensland and Australia-wide registry. By identifying an early stage of CAA, the research opens the door to potential treatments that could prevent the devastating effects of brain bleeds and dementia. The ultimate goal is the establishment of Australia's first CAA clinic, revolutionizing the care landscape for individuals with this condition. Beyond immediate clinical benefits, the project advances our understanding of CAA, fostering earlier identification, better care, and improved outcomes for those affected.